Richard B. Moss

A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation

Bonnie W. Ramsey, Jane C. Davies, Noel G. McElvaney et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text

Medicine, Molecular Biology, Molecular Genetics +8

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation

Frank J. Accurso, Steven M. Rowe, John P. Clancy et al. · New England Journal of Medicine · 2010 · 802 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

Valery T. Miller, John C. LaRosa, Vanessa M. Barnabei et al. · JAMA · 1995 · 605 citations

Medicine, Endocrinology, Pharmacology +15

Late Pulmonary Sequelae of Bronchopulmonary Dysplasia

William H. Northway, Richard B. Moss, Kathryn B. Carlisle et al. · New England Journal of Medicine · 1990 · 564 citations · Full text

Medicine, Clinical Sciences, Pediatrics +16

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

John P. Clancy, Steven M. Rowe, Frank J. Accurso et al. · Thorax · 2011 · 496 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16